| Autor: |
van der Eb MM; Academisch Ziekenhuis, vakgroep Heelkunde, Leiden., Schagen FH, van Ormondt H, Hoeben RC |
| Jazyk: |
Dutch; Flemish |
| Zdroj: |
Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 1998 Apr 11; Vol. 142 (15), pp. 840-4. |
| Abstrakt: |
The current treatment of haemophiliacs consists of injection of concentrates of blood clotting factors VIII (haemophilia A) and IX (haemophilia B). The inconvenience of the multiple injections needed, and the risk of transmission of infectious agents (HIV, hepatitis) prompted the development of alternative therapies. Gene therapy aims at introducing functional factor VIII and IX genes into the body cells of patients in order to make these cells produce the desired clotting factors. There are two strategies for gene therapy: (a) in the laboratory cells of the patient may be provided with the desired gene, followed by reintroduction of the cells that now produce factor VIII, into the patient (ex vivo strategy); (b) vectors with the desired genes may be injected into the patient in order to induce the modification (in vivo strategy) For both routes, the formal proof-of-principle has been acquired recently in animal experiments: cells modified by factor VIII or IX genes will produce adequate concentrations of the clotting products in plasma and will correct the bleeding tendency. Before the clinical evaluation and widespread application of the technology can be considered many technical problems have to be solved. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
